<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998461</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0907</org_study_id>
    <secondary_id>2021-A02135-36</secondary_id>
    <nct_id>NCT04998461</nct_id>
  </id_info>
  <brief_title>Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells</brief_title>
  <acronym>URISTEM</acronym>
  <official_title>Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is at risk for the development of chronic kidney disease but the involved mechanisms&#xD;
      are not known (Navarro et al. 2015). Establishing the link between obesity and kidney damage&#xD;
      is difficult. Indeed, kidney function measurement lacks precision in obese people (Lemoine et&#xD;
      al. 2014) and requires expensive methods such as measurement of 99mTc-DTPA clearance.&#xD;
      Biopsies are too invasive for the detection of emerging kidney damage or for the following of&#xD;
      the kidney function. Therefore new tools are required for the early identification of at risk&#xD;
      individuals for the kidney damage complication.&#xD;
&#xD;
      Mesenchymal stem cells may represent such a relevant tool. These cells are present in a large&#xD;
      number of organs, including kidney (Costa et al. 2020).&#xD;
&#xD;
      In addition to be differentiated cells progenitors (Dominici et al. 2006), they also support&#xD;
      immunosuppressive, anti-fibrotic and pro-angiogenic functions that have been used for the&#xD;
      treatment of kidney fibrosis (Usunier et al. 2014). Therefore, mesenchymal stem cells&#xD;
      contribute to tissue homeostasis and their alterations may reflect organ dysfunctions.&#xD;
      Indeed, mesenchymal stem cells from obese adipose tissue lose their immunosuppressive (Serena&#xD;
      et al. 2016) and differentiation (Gustafson et al. 2009) functions and contribute to fibrosis&#xD;
      (Keophiphath et al. 2009) and inflammation (Lee et al. 2010; Gustafson, Nerstedt, et Smith&#xD;
      2019). It is thus probable that kidney dysfunctions are associated with functional&#xD;
      alterations of kidney mesenchymal stem cells.&#xD;
&#xD;
      The collection of mesenchymal stem cells from kidney can easily be performed from urine and&#xD;
      next cultivated for amplification. They are called urine stem cells (USC).&#xD;
&#xD;
      From our experience with obese mouse adipose stem cells, we observed that functional changes&#xD;
      of stem cells preceded adipose tissue dysfunctions. Functional signatures of mesenchymal stem&#xD;
      cells are thus representative of changes occuring in the function of the tissue notably in&#xD;
      answer to obesity. These features could be used to identify obese people presenting ongoing&#xD;
      alterations of kidney function, before clinical manifestations of kidney dysfunction. Because&#xD;
      kidney mesenchymal stem cells are easy to isolate from urine, their collection is compatible&#xD;
      with the follow up of patients and can be applied to a large number of individuals, including&#xD;
      the younger. USC could represent a valuable tool to detect progression towards kidney damage.&#xD;
&#xD;
      In this project we plan to analyse USC alterations induced by obesity and to identify&#xD;
      signatures associated with the progression towards kidney damage and type 2 diabetes. The&#xD;
      goal is to evaluate USC as potential marker for the non invasive monitoring of patients in&#xD;
      answer to a need that is not achieved by the present available approaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of gene expression in USC (Urinary Stem Cells)</measure>
    <time_frame>inclusion day</time_frame>
    <description>High throughput sequencing will be used to compare USC (Urinary Stem Cells) for the differential expression of genes between the 4 populations (obese or lean patients, with or without alteration of the kidney function). A gene set enrichment analysis will be used to identify the main functions supported by USC from each patient, establishing a signature.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Obesity</condition>
  <condition>Stem Cells</condition>
  <condition>Diabetes type2</condition>
  <arm_group>
    <arm_group_label>Obese patients with normal renal function</arm_group_label>
    <description>estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2&#xD;
Body Mass Index (BMI) &gt; 30 kg/m2&#xD;
Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese patients with impaired renal function</arm_group_label>
    <description>estimated Glomerular Filtration Rate (eDFG) &lt; 60 ml/min/1.73 m2&#xD;
Body Mass Index (BMI) &gt; 30 kg/m2&#xD;
Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese patients with impaired renal function</arm_group_label>
    <description>estimated Glomerular Filtration Rate (eDFG) &lt; 60 ml/min/1.73 m2&#xD;
Body Mass Index (BMI) between 18 and 30 kg/m2&#xD;
Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese patients with normal renal function (control group)</arm_group_label>
    <description>estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2&#xD;
Body Mass Index (BMI) between 18 and 30 kg/m2&#xD;
Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>urine collection</intervention_name>
    <description>To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.</description>
    <arm_group_label>Non-obese patients with impaired renal function</arm_group_label>
    <arm_group_label>Non-obese patients with normal renal function (control group)</arm_group_label>
    <arm_group_label>Obese patients with impaired renal function</arm_group_label>
    <arm_group_label>Obese patients with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will focus on 4 groups of non-diabetic patients, namely:&#xD;
&#xD;
          1. obese patients with preserved renal function&#xD;
&#xD;
          2. obese patients with renal failure&#xD;
&#xD;
          3. non-obese patients with preserved renal function&#xD;
&#xD;
          4. non-obese patients with renal failure (study control group)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - For all participants :&#xD;
&#xD;
          -  Age between 18 and 60&#xD;
&#xD;
          -  Non diabetic (fasting blood glucose &lt;1.26 g/L)&#xD;
&#xD;
          -  Patient not having objected to participating in the research&#xD;
&#xD;
        Inclusion Criteria - For the obese group with normal renal function&#xD;
&#xD;
          -  eDFG ≥ 60 ml/min/1.73 m2&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h&#xD;
&#xD;
        Inclusion Criteria - For the obese group with impaired renal function&#xD;
&#xD;
          -  eDFG &lt; 60 ml/min/1.73 m2&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h&#xD;
&#xD;
        Inclusion Criteria - For the non-obese group with impaired renal function&#xD;
&#xD;
          -  eDFG &lt; 60 ml/min/1.73 m2&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2&#xD;
&#xD;
          -  Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h&#xD;
&#xD;
        Inclusion Criteria - For the non-obese group with normal renal function (control group)&#xD;
&#xD;
          -  eDFG ≥ 60 ml/min/1.73 m2&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2&#xD;
&#xD;
          -  Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria &lt; 0.15 g/24h&#xD;
&#xD;
        Exclusion Criteria - For all participants :&#xD;
&#xD;
          -  Acute renal failure within 3 months (defined as an increase of more than 50% in usual&#xD;
             creatinemia)&#xD;
&#xD;
          -  Inflammatory, infectious, cardiovascular or progressive neoplastic disease&#xD;
&#xD;
          -  Urinary pathology (malformation, infection, etc.)&#xD;
&#xD;
          -  Exclusion period of a previous study or already participating in a clinical research&#xD;
             protocol having an impact on the judgment criteria of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laetitia KOPPE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de néphrologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laetitia KOPPE, PhD</last_name>
    <phone>04 72 67 87 15</phone>
    <phone_ext>+33</phone_ext>
    <email>laetitia.koppe@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon SUD</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laetitia KOPPE, PhD</last_name>
      <phone>04 72 67 87 15</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.koppe@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bio-marker</keyword>
  <keyword>Chronic Kidney Diseases</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetes type2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

